{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T00:15:49Z","timestamp":1780359349873,"version":"3.54.1"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2018,7,28]],"date-time":"2018-07-28T00:00:00Z","timestamp":1532736000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2018,7,28]],"date-time":"2018-07-28T00:00:00Z","timestamp":1532736000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["K24AT007323"],"award-info":[{"award-number":["K24AT007323"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Rheumatol Rep"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1007\/s11926-018-0764-y","type":"journal-article","created":{"date-parts":[[2018,7,28]],"date-time":"2018-07-28T07:49:32Z","timestamp":1532764172000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["Artemisinins\u2014a Promising New Treatment for Systemic Lupus Erythematosus: a Descriptive Review"],"prefix":"10.1007","volume":"20","author":[{"given":"Xiaozhen","family":"Mu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenchen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,7,28]]},"reference":[{"key":"764_CR1","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1093\/rheumatology\/kew417","volume":"56","author":"LS Davis","year":"2017","unstructured":"Davis LS, Reimold AM. Research and therapeutics-traditional and emerging therapies in systemic lupus erythematosus. Rheumatology. 2017;56:100\u201313.","journal-title":"Rheumatology"},{"key":"764_CR2","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.jaut.2016.06.010","volume":"74","author":"L Durcana","year":"2016","unstructured":"Durcana L, Petrib M. Immunomodulators in SLE: clinical evidence and immunologic actions. J Autoimmun. 2016;74:73\u201384.","journal-title":"J Autoimmun"},{"key":"764_CR3","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/s10787-015-0239-y","volume":"23","author":"KD Rainsford","year":"2015","unstructured":"Rainsford KD, Parke AL, Clifford-Rashotte M, Kean WF. Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases. Inflammopharmacol. 2015;23:231\u201369.","journal-title":"Inflammopharmacol"},{"key":"764_CR4","first-page":"808","volume":"26","author":"C Wang","year":"1999","unstructured":"Wang C, Fortin PR, Li Y, Panaritis T, Gans M, Esdaile JM. Discontinuation of antimalarial drugs in systemic lupus erythematosus. J Rheumatol. 1999;26:808\u201315.","journal-title":"J Rheumatol"},{"key":"764_CR5","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1038\/eye.2016.298","volume":"31","author":"IH Yusuf","year":"2017","unstructured":"Yusuf IH, Sharma S, Luqmani R, Downes SM. Hydroxychloroquine retinopathy. Eye. 2017;31:828\u201345.","journal-title":"Eye"},{"key":"764_CR6","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1080\/14740338.2017.1269168","volume":"16","author":"C Ponticelli","year":"2017","unstructured":"Ponticelli C, Moroni G. Hydroxychloroquine in systemic lupus erythematosus (SLE). Expert Opin Drug Saf. 2017;16:411\u20139.","journal-title":"Expert Opin Drug Saf"},{"key":"764_CR7","first-page":"260","volume":"16","author":"YQ Lu","year":"2012","unstructured":"Lu YQ. The discovery and research progress of artemisinin. Life Science Research. 2012;16:260\u20135.","journal-title":"Life Science Research"},{"key":"764_CR8","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1146\/annurev-med-043015-123453","volume":"68","author":"J An","year":"2017","unstructured":"\u2022\u2022 An J, Minie M, Sasaki T, Woodward JJ, Elkon KB. Antimalarial drugs as immune modulators: new mechanisms for old drugs. Annu Rev Med. 2017;68:317\u201330. This comprehensive review summarizes and updates the chemistry of artemisinin drugs and their mechanisms of action. The authors emphasize how artemisinin drugs may impact multiple pathways of innate immunity and their current and future impact on systemic lupus erythematosus.","journal-title":"Annu Rev Med"},{"issue":"10","key":"764_CR9","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1016\/j.tips.2008.07.004","volume":"29","author":"S Krishna","year":"2008","unstructured":"Krishna S, Bustamante L, Haynes RK, Staines HM. Artemisinins: their growing importance in medicine. Trends Pharmacol Sci. 2008;29(10):520\u20137.","journal-title":"Trends Pharmacol Sci"},{"key":"764_CR10","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1038\/nm.2471","volume":"17","author":"T Yy","year":"2011","unstructured":"Yy T. The discovery of artemisinin (qinghao) and gifts from Chinese medicine. Nat Med. 2011;17:1217\u201320.","journal-title":"Nat Med"},{"key":"764_CR11","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1517\/14656560802678138","volume":"10","author":"A Schreiber","year":"2009","unstructured":"Schreiber A, Harter G, Schubert A, Bunjes D, Mertens T, Michel D. Antiviral treatment of cytomegalovirus infection and resistant strains. Exp Opin Pharmacother. 2009;10:191\u2013209.","journal-title":"Exp Opin Pharmacother"},{"key":"764_CR12","first-page":"39","volume":"4","author":"X Cui","year":"2010","unstructured":"Cui X, Wang Y, Kokudo N, Fang D, Tang W. Traditional Chinese medicine and related active compounds against hepatitis B virus infection. Biosci Trends. 2010;4:39\u201347.","journal-title":"Biosci Trends"},{"issue":"8","key":"764_CR13","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1016\/j.intimp.2011.02.028","volume":"11","author":"W Jiang","year":"2011","unstructured":"Jiang W, Li B, Zheng X, Liu X, Cen Y, Li J, et al. Artesunate in combination with oxacillin protect sepsis model mice challenged with lethal live methicillin-resistant Staphylococcus aureus (MRSA) via its inhibition on proinflammatory cytokines release and enhancement on antibacterial activity of oxacillin. Int Immunopharmacol. 2011;11(8):1065\u201373.","journal-title":"Int Immunopharmacol"},{"key":"764_CR14","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1007\/s11046-011-9445-3","volume":"172","author":"P Gautam","year":"2011","unstructured":"Gautam P, Upadhyay SK, Hassan W, Madan T, Sirdeshmukh R, Sundaram CS, et al. Transcriptomic and proteomic profile of Aspergillus fumigatus on exposure to artemisinin. Mycopathologia. 2011;172:331\u201346.","journal-title":"Mycopathologia"},{"key":"764_CR15","unstructured":"Xu LG, Chen P, Liang JS, Yi M, Wang Q, Ouyang D, et al. Therapeutic effect and mechanism of artesunate on experimental pulmonary fibrosis in rats. Clinical Medical Engineering. 2009;16(9):6\u20138."},{"key":"764_CR16","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1167\/iovs.10-5892","volume":"52","author":"XQ Wang","year":"2011","unstructured":"Wang XQ, Liu HL, Wang GB, Wu PF, Yan T, Xie J, et al. Effect of artesunate on endotoxin-induced uveitis in rats. Invest Ophthalmol Vis Sci. 2011;52:916\u20139.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"764_CR17","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.pharmthera.2013.12.001","volume":"142","author":"WE Ho","year":"2014","unstructured":"Ho WE, Peh HY, Chan TK, Fred Wong WS. Artemisinins: pharmacological actions beyond anti-malarial. Pharmacology & Therapeutics. 2014;142:126\u201339.","journal-title":"Pharmacology & Therapeutics"},{"key":"764_CR18","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.bbagen.2011.07.016","volume":"1820","author":"TR Daniels","year":"2012","unstructured":"Daniels TR, Bernabeu E, Rodr\u00edguez JA, Patel S, Kozman M, Chiappetta DA, et al. The transferrin receptor and the targeted delivery of therapeutic agents against cancer. Biochim Biophys Acta. 2012;1820:291\u2013317.","journal-title":"Biochim Biophys Acta"},{"issue":"6","key":"764_CR19","doi-asserted-by":"publisher","first-page":"38115","DOI":"10.1038\/srep38115","volume":"29","author":"ZM Lin","year":"2016","unstructured":"\u2022 Lin ZM, Yang XQ, Zhu FH, He SJ, Tang W, Zuo JP. Artemisinin analogue SM934 attenuate collagen-induced arthritis by suppressing T follicular helper cells and T helper 17 cells. Sci Rep. 2016;29(6):38115. This study demonstrates the immunosuppressive effects of artemisinin analogue SM934 on collagen-induced arthritis both in vitro and in vivo.","journal-title":"Sci Rep"},{"issue":"2","key":"764_CR20","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.trsl.2012.10.004","volume":"161","author":"MR Snyder","year":"2013","unstructured":"Snyder MR. Commentary on \u201cInhibitory effect of the antimalarial agent artesunate on collagen-induced arthritis in rats through nuclear factor kappa B and mitogen-activated protein kinase signaling pathway\u201d. Transl Res. 2013;161(2):85\u20138.","journal-title":"Transl Res"},{"key":"764_CR21","unstructured":"Cui XJ, Wang YY, Hou XQ, Pan L, Fu JX. Clinical observation of artesunate in the treatment of rheumatoid arthritis. Chin J Hosp Pharm. 2007;27(5):645\u20136."},{"key":"764_CR22","unstructured":"Wei S, Xu GG. Clinical observation of artesunate in the treatment of rheumatoid arthritis. Shanxi Journal of Medicine. 2008;37(5):457\u20138."},{"key":"764_CR23","unstructured":"Yu QB, Jin HL. Artesunate treatment on dermatosis: a clinical analysis of 90 cases. Journal of Bengbu Medical College. 1997;22(5):309\u201310."},{"issue":"4","key":"764_CR24","first-page":"241","volume":"31","author":"Q Zhou","year":"1998","unstructured":"Zhou Q, Gao YX, Jin HL. Effects of artesunate on experimental immunological myositis in animal model (in Chinese). Chinese Journal of Dermatology. 1998;31(4):241\u20133.","journal-title":"Chinese Journal of Dermatology"},{"key":"764_CR25","unstructured":"Ma J, Chen LH, Liao R, Xu SG, Li M, Xu DH, et al. Effect of artemether and dihydroartemisinin on scleroderma in mice. Chin J Chin Mat Med. 2009;34(2):204\u20137."},{"key":"764_CR26","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1016\/j.ijpara.2006.07.011","volume":"36","author":"J Golenser","year":"2006","unstructured":"Golenser J, Waknine JH, Krugliak M, Hunt NH, Grau GE. Current perspectives on the mechanism of action of artemisinins. Int J Parasitol. 2006;36:1427\u201341.","journal-title":"Int J Parasitol"},{"issue":"1","key":"764_CR27","first-page":"47","volume":"19","author":"JX Zhong","year":"1999","unstructured":"Zhong JX, Peng SQ, Zhang JY, Liang LQ. 25 cases of SLE treated with combination of traditional Chinese and western medicine. Chinese Journal of Integrated Traditional and Western Medicine. 1999;19(1):47\u20138.","journal-title":"Chinese Journal of Integrated Traditional and Western Medicine"},{"issue":"7","key":"764_CR28","first-page":"489","volume":"22","author":"JY Zhang","year":"2002","unstructured":"Zhang JY, Zhong JX, Shi ZY, Dai XY. Effect of artesunate and Lingdan tablet on T cell subsets in SLE patients. Chinese Journal of Integrated Traditional and Western Medicine. 2002;22(7):489.","journal-title":"Chinese Journal of Integrated Traditional and Western Medicine."},{"issue":"2","key":"764_CR29","first-page":"38","volume":"18","author":"JY Zhang","year":"2003","unstructured":"Zhang JY, Zhong JX, Peng SQ, Zhang FX. Study on the effect of artesunate and Lingdan tablet on IL-2 and sIL-2R in patients with SLE. Journal of Henan University of Chinese Medicine. 2003;18(2):38\u20139.","journal-title":"Journal of Henan University of Chinese Medicine"},{"issue":"3","key":"764_CR30","first-page":"169","volume":"22","author":"L Lu","year":"2002","unstructured":"Lu L. Study on effect of artemisinin and cordyceps sinensis in preventing recurrence of lupus nephritis. Chinese Journal of Integrated Traditional and Western Medicine. 2002;22(3):169\u201371.","journal-title":"Chinese Journal of Integrated Traditional and Western Medicine."},{"issue":"7","key":"764_CR31","first-page":"1673","volume":"22","author":"XX Huang","year":"2011","unstructured":"Huang XX. Clinical study of artesunate on immune function in patients with SLE. Lishizhen Medicine and Materia Medica Research. 2011;22(7):1673\u20134.","journal-title":"Lishizhen Medicine and Materia Medica Research"},{"issue":"1","key":"764_CR32","first-page":"51","volume":"30","author":"QB Yu","year":"1997","unstructured":"Yu QB, Gao YX. Clinical observation of artesunate in the treatment of 56 cases of lupus. Chinese Journal of Dermatology. 1997;30(1):51\u20132.","journal-title":"Chinese Journal of Dermatology."},{"issue":"3","key":"764_CR33","first-page":"173","volume":"21","author":"QB Yu","year":"1996","unstructured":"Yu QB, Jin HL. Clinical observation of artesunate in the treatment of 30 cases of SLE. Journal of Bengbu Medical College. 1996;21(3):173\u20134.","journal-title":"Journal of Bengbu Medical College"},{"issue":"1","key":"764_CR34","first-page":"56","volume":"12","author":"Chinese society of integrated Chinese and western medicine on dermatology","year":"1992","unstructured":"Chinese society of integrated Chinese and western medicine on dermatology. Five kinds of dermatological diseases: diagnosis and evaluation criteria of integrated traditional Chinese and western medicine. Chinese Journal of Integrated Traditional and Western Medicine. 1992;12(1):56\u20138.","journal-title":"Chinese Journal of Integrated Traditional and Western Medicine."},{"key":"764_CR35","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1093\/abbs\/gmq101","volume":"42","author":"XL Wu","year":"2010","unstructured":"Wu XL, Zhang WG, Shi XM, An P, Sun WS, Wang Z. Therapeutic effect of artemisinin on lupus nephritis mice and its mechanisms. Acta Biochim Biophys Sin. 2010;42:916\u201323.","journal-title":"Acta Biochim Biophys Sin"},{"key":"764_CR36","first-page":"608","volume":"35","author":"XL Wu","year":"2012","unstructured":"Wu XL, Sun WS, Shi XM, Wang Z, An P, Qiao CL. Effect of artemisinin on the expressions of GR\u03b1mRNA, GR\u03b2mRNA and P300\/CBP protein in lupus nephritis mice. Journal of Chinese Medical Materials. 2012;35:608\u201312.","journal-title":"Journal of Chinese Medical Materials"},{"key":"764_CR37","doi-asserted-by":"crossref","unstructured":"\u2022\u2022 Liang N, Zhong YC, Zhou J, Liu BH, Lu RR, Guan YZ, et al. Immunosuppressive effects of hydroxychloroquine and artemisinin combination therapy via the nuclear factor-\u03baB signaling pathway in lupus nephritis mice. Exp Ther Med. 2018;15:2436\u201342. This study demonstrates the immunosuppressive effect of artemisinin and hydroxychloroquine combination therapy, which may provide a novel method for the treatment of lupus nephritis. The underlying mechanisms of the combined treatment may be through regulation of the expression levels of cytokines, KLF15 and NF-kB.","DOI":"10.3892\/etm.2018.5708"},{"key":"764_CR38","first-page":"19","volume":"1","author":"LM Xu","year":"2002","unstructured":"Xu LM, Chen XR, Tu YY. Effect of dihydroartemisinin on BXSB lupus mice. Chinese Journal of Dermatovenereology of Integrated Traditional and Western Medicine. 2002;1:19\u201320.","journal-title":"Chinese Journal of Dermatovenereology of Integrated Traditional and Western Medicine"},{"key":"764_CR39","first-page":"676","volume":"23","author":"YJ Dong","year":"2003","unstructured":"Dong YJ, Li WD, Tu YY, Zou WZ, Xi HL, Lin ZB. Effect of dihydroartemisinin on autoantibodies production, TNF\u03b1 secretion and pathological changes of lupus nephritis in BXSB lupus mice. Chinese Journal of Integrated Traditional and Western Medicine. 2003;23:676\u20139.","journal-title":"Chinese Journal of Integrated Traditional and Western Medicine."},{"key":"764_CR40","first-page":"1125","volume":"19","author":"YJ Dong","year":"2003","unstructured":"Dong YJ, Li WD, Tu YY, Zhang HN, Zou WZ, Yang LL, et al. Effect and mechanism of dihydroartemisinin on BXSB lupus mice. Chinese Pharmacological Bulletin. 2003;19:1125\u20138.","journal-title":"Chinese Pharmacological Bulletin"},{"key":"764_CR41","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1016\/j.intimp.2006.03.004","volume":"6","author":"WD Li","year":"2006","unstructured":"Li WD, Dong YJ, Tu YY, Lin ZB. Dihydroarteannuin ameliorates lupus symptom of BXSB mice by inhibiting production of TNF-alpha and blocking the signaling pathway NF-kappa B translocation. Int Immunopharmacol. 2006;6:1243\u201350.","journal-title":"Int Immunopharmacol"},{"key":"764_CR42","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.intimp.2014.07.001","volume":"22","author":"XQ Huang","year":"2014","unstructured":"Huang XQ, Xie ZJ, Liu FF, Han CW, Zhang DY, Wang DW, et al. Dihydroartemisinin inhibits activation of the Toll-like receptor 4 signaling pathway and production of type I interferon in spleen cells from lupus-prone MRL\/lpr mice. Int Immunopharmacol. 2014;22:266\u201372.","journal-title":"Int Immunopharmacol"},{"issue":"7","key":"764_CR43","first-page":"617","volume":"30","author":"YW You","year":"2014","unstructured":"You YW, Liao PH, Yang FF, Lin X. Regulating effect of dihydroartemisinin on expression of fractalkine in renal cortex of lupus-prone MRL\/lpr mice. Immunological Journal. 2014;30(7):617\u201322.","journal-title":"Immunological Journal"},{"key":"764_CR44","first-page":"1637","volume":"31","author":"M Huang","year":"2015","unstructured":"\u2022 Huang M, Jin XK, Cai QC, Li M, Lin ZB, Li WD. Effect of dihydroartemisinin on lupus mice and its relationship with SIGIRR induced immune negative regulation. Chinese Journal of Immunology. 2015;31:1637\u201341. 1647. The authors observe the relationship between the therapeutic effect of dihydroartemisinin and its molecular mechanism and signal pathway in lupus mouse model.","journal-title":"Chinese Journal of Immunology"},{"key":"764_CR45","first-page":"25","volume":"2","author":"WX Zhu","year":"2003","unstructured":"Zhu WX, Gu J. Effects of artesunate on interleukin-6 and transforming growth factor \u03b2 in renal tissue of lupus-like mice. Chinese Journal of Dermatovenereology of Integrated Traditional and Western Medicine. 2003;2:25\u20137.","journal-title":"Chinese Journal of Dermatovenereology of Integrated Traditional and Western Medicine."},{"key":"764_CR46","first-page":"318","volume":"20","author":"WX Zhu","year":"2004","unstructured":"Zhu WX, Gu J. Effects of artesunate on serum level of interleukin-6 and transforming growth factor \u03b2 in lupus-like mice. Chinese Journal of leprosy and skin diseases. 2004;20:318\u20139.","journal-title":"Chinese Journal of leprosy and skin diseases"},{"issue":"4","key":"764_CR47","first-page":"5","volume":"11","author":"OY Jin","year":"2007","unstructured":"Jin OY, Zhang HY, Xu T, Zhao SN, Zhou KX, Sun LY. Pathological change and mechanism of artesunate treatment for lupus nephritis in MRL\/lpr mice. Journal of Clinical Medicine in Practice. 2007;11(4):5\u20139.","journal-title":"Journal of Clinical Medicine in Practice"},{"key":"764_CR48","first-page":"615","volume":"27","author":"XD Lin","year":"2008","unstructured":"Lin XD, Zhong JX, Qi SJ, Zhang FX. Effects of artesunate on the expression of CD4, CD8 and CD54 on peripheral blood lymphocytes in lupus like mice. Shandong J Tradit Chin Med. 2008;27:615\u20137.","journal-title":"Shandong J Tradit Chin Med"},{"key":"764_CR49","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1038\/cmi.2009.58","volume":"6","author":"OY Jin","year":"2009","unstructured":"Jin OY, Zhang HY, Gu ZF, Zhao SN, Xu T, Zhou KX, et al. A pilot study of the therapeutic efficacy and mechanism of artesunate in the MRL\/lpr murine model of systemic lupus erythematosus. Cellular & Molecular Immunology. 2009;6:461\u20137.","journal-title":"Cellular & Molecular Immunology"},{"issue":"7","key":"764_CR50","first-page":"1","volume":"14","author":"H Wang","year":"2010","unstructured":"Wang H, Jiang B, Zhang HY, Liu BJ, Sun LY. Artesunate relieves lupus nephritis by inhibiting the expression of ICAM-1. Journal of Clinical Medicine in Practice. 2010;14(7):1\u20133.","journal-title":"Journal of Clinical Medicine in Practice."},{"key":"764_CR51","doi-asserted-by":"publisher","first-page":"2445","DOI":"10.1002\/art.30392","volume":"63","author":"LF Hou","year":"2011","unstructured":"Hou LF, He SJ, Li X, Yang Y, He PL, Zhou Y, et al. Oral administration of artemisinin analog SM934 ameliorates lupus syndromes in MRL\/lpr mice by inhibiting Th1 and Th17 cell responses. Arthritis Rheum. 2011;63:2445\u201355.","journal-title":"Arthritis Rheum"},{"issue":"2","key":"764_CR52","doi-asserted-by":"publisher","first-page":"e32424","DOI":"10.1371\/journal.pone.0032424","volume":"7","author":"LF Hou","year":"2012","unstructured":"Hou LF, He SJ, Li X, Wan CP, Yang Y, Zhang XH, et al. SM934 treated lupus-prone NZB \u00d7 NZW F1 mice by enhancing macrophage interleukin-10 production and suppressing pathogenic T cell development. PLoS One. 2012;7(2):e32424.","journal-title":"PLoS One"},{"key":"764_CR53","doi-asserted-by":"crossref","unstructured":"\u2022\u2022 Wu YW, He SJ, Bai BX, Zhang LY, Xue L, Lin ZM, et al. Therapeutic effects of the artemisinin analog SM934 on lupus-prone MRL\/lpr mice via inhibition of TLR-triggered B-cell activation and plasma cell formation. Cell Mol Immunol. 2016;13:379\u201390. This study investigates the therapeutic effects of a modified dosage regimen of artemisinin analogue SM934 on lupus-prone MRL\/lpr mice and explores its effects on B cell responses in SLE. The authors conclude that a twice daily dosing regimen of SM 934 has therapeutic effects on lupus-prone MRL\/lpr mice by suppressing B cell activation and plasma cell formation.","DOI":"10.1038\/cmi.2015.13"},{"key":"764_CR54","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/S0065-2776(08)60342-9","volume":"37","author":"AN Theofilopoulos","year":"1985","unstructured":"Theofilopoulos AN, Dixon FJ. Murine models of systemic lupus erythematosus. Adv Immunol. 1985;37:269\u2013390.","journal-title":"Adv Immunol"},{"issue":"2","key":"764_CR55","doi-asserted-by":"crossref","first-page":"858","DOI":"10.4049\/jimmunol.134.2.858","volume":"134","author":"H Jyonouchi","year":"1985","unstructured":"Jyonouchi H, Kincade PW, Good RA. Age-dependent changes in B lymphocyte lineage cell populations of autoimmune-prone BXSB mice. J Immunol. 1985;134(2):858\u201364.","journal-title":"J Immunol"},{"issue":"1","key":"764_CR56","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1177\/0961203316651738","volume":"26","author":"X Feng","year":"2017","unstructured":"\u2022\u2022 Feng X, Chen W, Xiao L, Gu F, Huang J, Tsao BP, et al. Artesunate inhibits type I interferon-induced production of macrophage migration inhibitory factor in patients with systemic lupus erythematosus. Lupus. 2017;26(1):62\u201372. These authors report the effects and potential immune mechanisms of artesunate and find that artesunate inhibits macrophage migration inhibitory factor, and thus may have therapeutic potential for SLE-associated atherosclerosis.","journal-title":"Lupus"},{"issue":"1","key":"764_CR57","first-page":"1","volume":"20","author":"B Zani","year":"2014","unstructured":"Zani B, Gathu M, Donegan S, Olliaro PL, Sinclair D. Dihydroartemisinin-piperaquine for treating uncomplicated Plasmodium falciparum malaria. Cochrane Database Syst Rev. 2014;20(1):1\u2013160.","journal-title":"Cochrane Database Syst Rev"},{"issue":"11","key":"764_CR58","doi-asserted-by":"publisher","first-page":"e0164963","DOI":"10.1371\/journal.pone.0164963","volume":"11","author":"SD Kovacs","year":"2016","unstructured":"\u2022 Kovacs SD, van Eijk AM, Sevene E, Dellicour S, Weiss NS, Emerson S, et al. The safety of artemisinin derivatives for the treatment of malaria in the 2nd or 3rd trimester of pregnancy: a systematic review and meta-analysis. PLoS One. 2016;11(11):e0164963. This study provides a comprehensive review of the safety of artemisinin derivatives for the treatment of malaria during pregnancy.","journal-title":"PLoS One"},{"issue":"5","key":"764_CR59","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.trstmh.2003.11.001","volume":"98","author":"S Toovey","year":"2004","unstructured":"Toovey S, Jamieson A. Audiometric changes associated with the treatment of uncomplicated falciparum malaria with co-artemether. Trans R Soc Trop Med Hyg. 2004;98(5):261\u20137.","journal-title":"Trans R Soc Trop Med Hyg"},{"issue":"2","key":"764_CR60","doi-asserted-by":"publisher","first-page":"211","DOI":"10.4269\/ajtmh.2006.74.211","volume":"74","author":"R Hutagalung","year":"2006","unstructured":"Hutagalung R, Htoo H, Nwee P, Arunkamomkiri J, Zwang J, Carrara VI, et al. A case-control auditory evaluation of patients treated with artemether-lumefantrine. Am J Trop Med Hyg. 2006;74(2):211\u20134.","journal-title":"Am J Trop Med Hyg"},{"issue":"7487","key":"764_CR61","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1136\/bmj.330.7487.334","volume":"330","author":"JR Aceng","year":"2005","unstructured":"Aceng JR, Byarugaba JS, Tumwine JK. Rectal artemether versus intravenous quinine for the treatment of cerebral malaria in children in Uganda: randomised clinical trial. BMJ. 2005;330(7487):334.","journal-title":"BMJ"},{"issue":"1","key":"764_CR62","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2174\/157488606775252584","volume":"1","author":"F Nosten","year":"2006","unstructured":"Nosten F, McGready R, d'Alessandro U, Bonell A, Verhoeff F, Menendez C, et al. Antimalarial drugs in pregnancy: a review. Curr Drug Saf. 2006;1(1):1\u201315.","journal-title":"Curr Drug Saf"},{"key":"764_CR63","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/S1473-3099(11)70339-5","volume":"12","author":"R McGready","year":"2012","unstructured":"McGready R, Lee SJ, Wiladphaingern J, Ashley EA, Rijken MJ, Boel M, et al. Adverse effects of falciparum and vivax malaria and the safety of antimalarial treatment in early pregnancy: a population-based study. Lancet Infect Dis. 2012;12:388\u201396.","journal-title":"Lancet Infect Dis"},{"issue":"2","key":"764_CR64","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/s10549-017-4261-1","volume":"164","author":"C von Hagens","year":"2017","unstructured":"\u2022 von Hagens C, Walter-Sack I, Goeckenjan M, Osburg J, Storch-Hagenlocher B, Sertel S, et al. Prospective open uncontrolled phase I study to define a well-tolerated dose of oral artesunate as add-on therapy in patients with metastatic breast cancer (ARTIC M33\/2). Breast Cancer Res Treat. 2017;164(2):359\u201369. This study describes safety of use oral artesunate and emphasizes that safety monitoring should include reticulocytes, audiological and neurological exploration for cancer patients.","journal-title":"Breast Cancer Res Treat"}],"container-title":["Current Rheumatology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11926-018-0764-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-018-0764-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-018-0764-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,4]],"date-time":"2023-09-04T00:51:46Z","timestamp":1693788706000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11926-018-0764-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,28]]},"references-count":64,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["764"],"URL":"https:\/\/doi.org\/10.1007\/s11926-018-0764-y","relation":{},"ISSN":["1523-3774","1534-6307"],"issn-type":[{"value":"1523-3774","type":"print"},{"value":"1534-6307","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,28]]},"assertion":[{"value":"28 July 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"55"}}